FDA’s First Breakthrough Designations Continue Vertex Kalydeco’s Regulatory Successes
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Label expansion efforts for Vertex’s cystic fibrosis therapy will be claims taken through FDA’s new review pathway; the initial product could reach more patients more quickly and serve as a guide to how the agency will handle drugs earmarked for streamlined development and approval.